$Arcturus Therapeutics(ARCT.US$
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
https://finance.yahoo.com/news/arcturus-announces-self-amplifying-covid-113000171.html
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
https://finance.yahoo.com/news/arcturus-announces-self-amplifying-covid-113000171.html
1
$强生(JNJ.US$
Dengue compound backed by J&J shows potency against the virus and all known variants in mice
https://www.fiercebiotech.com/research/dengue-pill-backed-by-j-j-shows-potency-against-virus-and-all-known-variants-mice
Dengue compound backed by J&J shows potency against the virus and all known variants in mice
https://www.fiercebiotech.com/research/dengue-pill-backed-by-j-j-shows-potency-against-virus-and-all-known-variants-mice
$Arcturus Therapeutics(ARCT.US$Arcturus 宣布批准一项临床试验申请,以推进 ARCT-154,这是一种针对 SARS-CoV-2 Delta 变体和其他令人担忧的变体的下一代 STARR™ mRNA 疫苗
https://finance.yahoo.com/news/arcturus-announces-approval-clinical-trial-130000038.html
https://finance.yahoo.com/news/arcturus-announces-approval-clinical-trial-130000038.html
已翻译
1
3
$Vir Biotechnology(VIR.US$
Some preliminary positive results for sotrovimab
"The primary efficacy analysis of all 1,057 patients in the COMET-ICE trial demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalization for more than 24 hours or death due to any cause, by Day 29 compared to placebo, meeting the primary endpoint of the trial"
https://www.globenewswire.com/news-release/2021/06/21/2250117/0/en/GSK-and-Vir-Biotechnology-Announce-Continuing-Progress-of-the-COMET-Clinical-Development-Program-for-Sotrovimab.html
https://www.reuters.com/article/health-coronavirus-gsk-usa/study-confirms-gsk-vir-antibody-drug-reduces-hospitalization-death-in-covid-19-patients-idUSL3N2O32Q9...
Some preliminary positive results for sotrovimab
"The primary efficacy analysis of all 1,057 patients in the COMET-ICE trial demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalization for more than 24 hours or death due to any cause, by Day 29 compared to placebo, meeting the primary endpoint of the trial"
https://www.globenewswire.com/news-release/2021/06/21/2250117/0/en/GSK-and-Vir-Biotechnology-Announce-Continuing-Progress-of-the-COMET-Clinical-Development-Program-for-Sotrovimab.html
https://www.reuters.com/article/health-coronavirus-gsk-usa/study-confirms-gsk-vir-antibody-drug-reduces-hospitalization-death-in-covid-19-patients-idUSL3N2O32Q9...
2
$Arcturus Therapeutics(ARCT.US$
02 June 2021
Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics
https://www.prnewswire.com/news-releases/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna-polymerase-for-human-and-animal-therapeutics-301303621.html
02 June 2021
Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics
https://www.prnewswire.com/news-releases/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna-polymerase-for-human-and-animal-therapeutics-301303621.html
$富途控股(FUTU.US$
The companies, FUTU AND TIGR, disclosed during earnings calls last month they are applying for licenses in Singapore and the U.S. that would allow local customers to trade digital currencies.
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
The companies, FUTU AND TIGR, disclosed during earnings calls last month they are applying for licenses in Singapore and the U.S. that would allow local customers to trade digital currencies.
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
$向上融科(TIGR.US$
The companies, and , disclosed during earnings calls last month they are applying for licenses in Singapore and the U.S. that would allow local customers to trade digital currencies.
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
The companies, and , disclosed during earnings calls last month they are applying for licenses in Singapore and the U.S. that would allow local customers to trade digital currencies.
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal